AbbVie announces first provincial reimbursements for Venclexta (venetoclax) in combination with azacitidine for acute myeloid leukaemia patients

10 February 2022 - Following the signing of an agreement between AbbVie and the pan-Canadian Pharmaceutical Alliance, Quebec, Saskatchewan, and ...

Read more →